FDA approves Novartis Rhapsido for symptomatic dermographism in adults
NVS•The FDA approved Novartis’ Rhapsido for adults with symptomatic dermographism inadequately controlled by H1 antihistamines, making it the first approved treatment for the condition. In Phase III RemIND data, complete hive resolution at Week 12 occurred in 29.3% of patients taking Rhapsido, versus 14.0% on placebo.
1. FDA approval
The FDA approved Novartis’ Rhapsido (remibrutinib) for adults with symptomatic dermographism inadequately controlled by H1 antihistamines. It is the first approved treatment for the condition and adds to Rhapsido’s earlier U.S. use in chronic spontaneous urticaria.
2. Phase III results
Phase III RemIND data showed complete hive resolution at Week 12 in 29.3% of patients taking Rhapsido, compared with 14.0% on placebo.
